首页 >  威科专题 > 专题查看

   编者按

2017年11月4日修订的《中华人民共和国反不正当竞争法》亮点颇多。其中,反贿赂条款的适用,自修订以来通过2018年一年的过渡和适应期,以及2019年的较多执法案例,在争议中不断总结共识,这两年的执法案例以及从中体现出的执法口径和执法理念对于此后企业进行商业模式的合规评估尤为重要。威科先行携手上海邦信阳中建中汇律师事务所张士海律师团队,专业打磨中英双语的重量级内容,对2018年到2019年的商业贿赂执法案例和相关文件进行系统梳理和总结,结合商业实践需要对贿赂的合规难点、要点、重点以及中国的反贿赂趋势等进行提示,力争成为您从事中国反商业贿赂合规的重要参考和工具。

   前言/ Preface

2017年11月4日修订的《中华人民共和国反不正当竞争法》(以下简称“新竞争法”、“新法”)亮点颇多,其中的商业贿赂界定突出职务、职权利益交换这一本质特征的理念进步备受瞩目。从整体上看,新竞争法对商业贿赂的界定更为明晰,其通过对贿赂行为的重新界定在很大程度上缩小了商业贿赂行为的范围。但是,如何在商业实践中把握具体商业模式与新竞争法中禁止的贿赂行为的界限仍然存在很多挑战和不确定性,同时,新竞争法在施行中也存在诸多需要进一步厘清的问题。

新竞争法的反贿赂条款适用,自修订以来通过2018年一年的过渡和适应期,以及2019年的较多执法案例,在争议中不断总结共识。这两年的执法案例以及从中体现出的执法口径和执法理念对于此后企业进行商业模式的合规评估尤为重要。本报告将对2018年到2019年的商业贿赂执法案例和相关文件进行系统梳理和总结,结合商业实践需要对贿赂的合规难点、要点、重点以及中国的反贿赂趋势等进行提示,力争使本报告成为我们的客户和从事中国反商业贿赂合规的重要参考和工具。

本报告共包括八个部分,分别是新法实施后的执法详情(包括2018年到2019年我们收集到的执法案件)、重点案例和热点商业模式分析(主要涉及医药、医疗器械行业)、商业贿赂的企业与高管责任、商业贿赂的民事赔偿责任、商业贿赂行刑衔接问题、违法所得的计算、难点和风险敞口、执法趋势。企业可以根据目录查找自己关心的内容进行阅读。例如关心激励专业人士的,可以在“新法实施后的执法详情”中查看,我们总结了收集到案例中获得从轻、减轻处罚案件的量罚情节。

本报告是我们中国商业贿赂执法报告系列的第一份报告。此后我们每年都会针对上一年度的行政执法发布对应的执法报告。此次报告包含2018和2019两个年度,是因为新竞争法2018年1月1日正式实施,我们希望系列报告能够涵盖新竞争法实施以后尽量全的案例,实现较好的全面性;也希望我们的客户通过这一份报告就可以较好地掌握执法趋势、力度、重点、难点,可以在日常合规工作中作为简易的参考。

The Anti-Unfair Competition Law of the People's Republic of China (the “New Competition Law” or the “New Law”), amended on November 4, 2017 and came into effect on January 1, 2018, has quite a few exciting changes. Among them, a better-defined commercial bribery, which highlights the bribery essence of exchanging the entrusted authorization with interests, captures lots of attention. In general, the New Competition Law defines commercial bribery more clearly (narrowing down the scope of commercial bribery to a large extent). However, challenges and uncertainties remain and there are many issues that need to be further clarified in the implementation and enforcement of the New Competition Law.

By far, the practice of commercial bribery clause under the New Competition Law has gone through more than two years’ transition and adaptation. The enforcer, Administration of Market Regulation (“AMR”, hereinafter this acronym also represents its precedent Administration of Industry and Commerce (AIC)), has shown their experience and maturity in using the new clause in protecting fair competition of the market. By looking at the enforcement cases by AMR, this Report on Anti-Commercial-Bribery Enforcement of China (2018. 01-2019. 06) (“Report”) systematically summarizes and reviews AMR’s enforcement from the day when the New Law came into effect to the first half year of 2020.

   声明/ Statement

本报告仅代表张士海律师团队观点,不得视为上海邦信阳中建中汇律师事务所或其律师出具的正式法律意见或建议。考虑到法律的原则性以及竞争法商业贿赂条款尚存诸多需要进一步明确的问题,我们的观点仅供学习交流使用,报告随着立法和执法的变化需要调整,不保证在任何时间和地点均不会被挑战。

未经本律师团队书面同意,不得转载或使用本报告中的任何内容。如对报告内容进行引用的,请务必标明出处。本报告主要提供给公司客户作为参考和交流,收到本报告的公司仅限内部传阅,请勿将此报告提供给公司外的任何第三方(张士海律师团队将本报告全文正式对外公开的除外)。如果您有兴趣仅本报告话题做进一步交流或探讨,欢迎联系我们。具体联系方式请见报告最后“团队简介”部分。

This Report represents opinions of Zhang Shihai’s Team only, which shall not be deemed as formal legal advice or opinions given by Boss Young Attorneys-at-Law or its attorney. Due to the flexibility of the law as well as the unsettled issues of the commercial bribery clause, our opinions in this Report are only for the purpose of discussion and study. The Report is subject to the change of legislation and enforcement; we do not guarantee that the Report will not be challenged anytime in anywhere.

You shall not reprint or use any content of this Report unless you have obtained a prior written permit by Zhang Shihai’s team. And if you quote the content of this Report, please ensure to indicate the origin. This Report is made mainly for the purpose to give reference for our clients, the companies receiving this Report should only circulate it within the company, do not share this Report to any third party provided that Zhang Shihai’s Team has published this entire Report to public.

   商业贿赂相关的企业与高管责任

   执法趋势、难点与风险

   CLUES FOR COMMERCIAL BRIBERY ENFORCEMENT

   LIABILITIES OF COMPANY AND MANAGEMENT